New data shows the state of New Mexico earned US$24.1 million in revenue from medical cannabis during the first quarter of 2018, a 27-percent increase from the same period last year.

Ultra Health, a dispensary operator in the US market, issued a report on the performance of patient revenues from the New Mexico Medical Cannabis Program in the state.

According to the information presented by Ultra Health, retail sales averaged US$689,298 per producer for the quarter, while the median amounted to US$419,945.

Patient population continued to increase as well, with 4,300 new patients added during Q1 2018. As of March 31, patient enrolment in New Mexico had reached 50,954 active legal cannabis users.

“As the decade-old New Mexico Medical Cannabis Program matures, the leading competitors are strengthening market share which likely will accelerate consolidation in the industry,” Ultra Health wrote.

State working towards complete legalization

New Mexico has had a medical cannabis bill since 2007. The state is now preparing to completely legalize the drug by asking state voters to decide on the issue.

“Marijuana prohibition in New Mexico has clearly failed,” said Emily Kaltenbach, New Mexico state director with the Drug Policy Alliance, after the bill to tax and regulate the drug passed the Senate Rules Committee in the state.

“It hasn’t reduced use and instead has resulted in mass criminalization, appalling racial disparities, and enormous fiscal waste,” Kaltenbach added.

The data from Ultra Health indicates the top five producers of cannabis in the state secured 44 percent of patient sales during this past quarter. Ultra Health states that the largest retail product remains cannabis flower, with a reported 3,427 pounds sold during the first quarter of 2018.

The report also includes a cannabis market development projection for New Mexico, with a calculation of over US$105 million in revenue for 2018 thanks to a patient count of 65,000 by the end of the year.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less